• Fulfilling

    Potential

    With the Science of Enzymes

  • Fulfilling

    Potential

    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping

    Patients

    Fulfill Their Potential

News & Media

Alcresta Therapeutics’ RELiZORB® (immobilized lipase) cartridge shows long-term effectiveness in enterally fed patients with cystic fibrosis

Nov 11, 2020

NEWTON, MA, November 11, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the publication of a 12-month observational study in Journal of Pediatric Gastroenterology & Nutrition that evaluated the effectiveness of long-term RELiZORB® (iMMOBILIZED LIPASE) Cartridge use in enterally fed patients with cystic fibrosis.

Alcresta Therapeutics Announces Appointment of Jason Weiner as Chief Commercial Officer

Jul 27, 2020

Newton, MA – July 27, 2020 – Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Jason Weiner as its Chief Commercial Officer (CCO) effective July 27, 2020.

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB®

Jun 25, 2019

Warren, N.J. – June 25, 2019 – Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a consensus statement supporting the clinical outcomes of RELiZORB® (immobilized lipase cartridge) and advocating for improved payer coverage and patient access.